After several years of decline, Moderna (MRNA) stock saw a double-digit percentage increase this past January. This biotechnology company, which rose to prominence during the pandemic due to its rapid development of a COVID-19 vaccine using mRNA technology, has recently been hampered by these same two core elements: the U.S. terminated approximately $500 million in funding for mRNA vaccine development last year, and simultaneously, revenue from its COVID-19 vaccine has fallen far below peak levels due to declining demand.
The company’s recent developments present a mixed picture: In 2024, its Respiratory Syncytial Virus (RSV) vaccine was approved for market, but just a few months prior, a Cytomegalovirus (CMV) vaccine candidate failed in a Phase III clinical trial. For investors considering Moderna, the following information warrants close attention.
Looking back at its development trajectory, this biotech firm is at a critical turning point. The company is currently focused on building a seasonal vaccine business line to support research and development investments across its broader pipeline, which includes oncology and rare disease treatments. Moderna currently has two COVID-19 vaccines and its RSV vaccine on the market, and plans to expand its seasonal product portfolio with an influenza vaccine. Earlier this month, the U.S. Food and Drug Administration (FDA) declined to review the application for its flu candidate due to issues with vaccine dosage levels in the study’s control group. However, after the company submitted a revised regulatory plan, the FDA reversed its stance and initiated the review process. If all goes well, this vaccine could be available before the next flu season.
According to the outlook released earlier this year, Moderna projects that growth in seasonal vaccine sales will enable the company to achieve cash flow breakeven by 2028. The company recently reiterated its forecast of 10% revenue growth for the current year. Concurrently, its R&D pipeline continues to advance, including a tumor vaccine candidate currently in Phase III clinical studies.
Although it faced the setback of the FDA’s hold on its flu vaccine application a few weeks ago, the issue was resolved swiftly. The persistent challenging regulatory environment means this biotech company may still face difficulties in the short term. However, with a rich R&D pipeline containing multiple late-stage candidates, its long-term prospects remain promising. This suggests that Moderna’s stock price may not skyrocket overnight, but for patient investors seeking a biotech company with sustainable growth potential, it could represent a quality choice.
It is worth noting that billionaire Philippe Laffont, founder of Coatue Management, recently established a position in Moderna, purchasing 200,000 shares. For this hedge fund, which manages $39 billion in 13F securities, its top four holdings are all in the technology sector, with Taiwan Semiconductor Manufacturing Company (TSMC) leading the way, comprising over 6.5% of the portfolio. Although this Moderna trade represents only 0.01% of Coatue’s portfolio, the move by this investor, known for identifying winning technology plays, has still captured market attention.
Moderna’s stock soared in the early days of the pandemic following the launch of its COVID-19 vaccine, but has accumulated a decline of over 70% in the past three years as vaccine demand waned. Now, through cost control and a strategic shift, the company is refocusing on long-term development: leveraging its existing business from the COVID-19 and RSV vaccines, it plans to expand its respiratory product line with the flu vaccine, using revenue from this segment to fund R&D in oncology and rare diseases. Currently, its pipeline includes an oncology candidate that has entered Phase III trials, alongside numerous other drugs in ongoing development.
Analysis suggests that while Laffont has not publicly disclosed his reasons for building the position, he clearly recognizes Moderna’s innovative capability as an mRNA technology platform and sees its potential to embark on a new growth cycle. This investor, who has already reaped significant returns from investing in CoreWeave, may be on the lookout for new growth opportunities.
